Cargando…

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin

Progestin resistance is a major obstacle to treating early stage, well-differentiated endometrial cancer as well as recurrent endometrial cancer. The mechanism behind the suboptimal response to progestin is not well understood. The PTEN tumor suppressor gene is frequently mutated in type I endometri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pant, Alok, Lee, Irene I., Lu, Zhenxiao, Rueda, Bo R., Schink, Julian, Kim, J. Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404036/ https://www.ncbi.nlm.nih.gov/pubmed/22911820 http://dx.doi.org/10.1371/journal.pone.0041593

Ejemplares similares

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
por: Zhao, Yuan-Yuan, et al.
Publicado: (2014)

Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells
por: Djuzenova, Cholpon S., et al.
Publicado: (2019)

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures
por: Narayan, Ravi S., et al.
Publicado: (2017)

Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
por: Rehan, Mohd, et al.
Publicado: (2014)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
por: Hudis, Clifford, et al.
Publicado: (2013)

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells
por: Malkomes, Patrizia, et al.
Publicado: (2016)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
por: Ahn, Daniel H., et al.
Publicado: (2015)

Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
por: Wilson, Jacob M, et al.
Publicado: (2015)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
por: Gong, Baocheng, et al.
Publicado: (2021)

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma
por: Al-Saffar, Nada M. S., et al.
Publicado: (2018)

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
por: Gao, Hai-Ling, et al.
Publicado: (2023)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
por: Xiang, Ru-Fang, et al.
Publicado: (2017)

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
por: Chen, Meiling, et al.
Publicado: (2022)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
por: Meng, Jieru, et al.
Publicado: (2013)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
por: Gong, Baocheng, et al.
Publicado: (2022)

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
por: Agarwal, Ekta, et al.
Publicado: (2014)

MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition
por: Sun, Dingqi, et al.
Publicado: (2020)

The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
por: Cui, Haiyan, et al.
Publicado: (2020)

MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation
por: Jin, Piaopiao, et al.
Publicado: (2016)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Richter, Anna, et al.
Publicado: (2021)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
por: Xing, Yan, et al.
Publicado: (2019)

Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility
por: Che, Huan-yong, et al.
Publicado: (2014)

FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt
por: Dong, Jing, et al.
Publicado: (2017)

Sensitization of Cancer Cells through Reduction of Total Akt and Downregulation of Salinomycin-Induced pAkt, pGSk3β, pTSC2, and p4EBP1 by Cotreatment with MK-2206
por: Choi, Ae-Ran, et al.
Publicado: (2014)

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206
por: Chorner, Paige M., et al.
Publicado: (2018)

Corrigendum to “Sensitization of Cancer Cells through Reduction of Total Akt and Downregulation of Salinomycin-Induced pAkt, pGSk3β, pTSC2, and p4EBP1 by Cotreatment with MK-2206”
por: Choi, Ae-Ran, et al.
Publicado: (2015)

Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma
por: Xia, Yuan-Zheng, et al.
Publicado: (2016)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma
por: Wei, Lina, et al.
Publicado: (2023)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ho6nt97ucvfg8986jm0amoit23